Meritage Portfolio Management Takes $570,000 Position in Integra Lifesciences Holdings Corp (NASDAQ:IART)

Meritage Portfolio Management acquired a new stake in Integra Lifesciences Holdings Corp (NASDAQ:IART) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,209 shares of the life sciences company’s stock, valued at approximately $570,000.

Several other hedge funds also recently modified their holdings of IART. First Trust Advisors LP grew its position in shares of Integra Lifesciences by 922.1% in the second quarter. First Trust Advisors LP now owns 211,299 shares of the life sciences company’s stock valued at $11,801,000 after purchasing an additional 190,626 shares in the last quarter. Fisher Asset Management LLC grew its position in shares of Integra Lifesciences by 0.7% in the second quarter. Fisher Asset Management LLC now owns 781,166 shares of the life sciences company’s stock valued at $43,628,000 after purchasing an additional 5,698 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Integra Lifesciences by 27.1% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 10,268 shares of the life sciences company’s stock valued at $573,000 after purchasing an additional 2,190 shares in the last quarter. ARP Americas LP purchased a new stake in shares of Integra Lifesciences in the second quarter valued at approximately $302,000. Finally, SG Americas Securities LLC grew its position in shares of Integra Lifesciences by 717.7% in the second quarter. SG Americas Securities LLC now owns 60,700 shares of the life sciences company’s stock valued at $3,390,000 after purchasing an additional 53,277 shares in the last quarter. 82.17% of the stock is owned by institutional investors and hedge funds.

Integra Lifesciences stock remained flat at $$62.80 during mid-day trading on Friday. The company had a trading volume of 218,942 shares, compared to its average volume of 419,679. The company has a market capitalization of $5.37 billion, a price-to-earnings ratio of 25.95, a price-to-earnings-growth ratio of 1.97 and a beta of 1.09. Integra Lifesciences Holdings Corp has a 52 week low of $42.14 and a 52 week high of $66.41. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.82 and a current ratio of 2.76. The company has a 50-day simple moving average of $57.27.

Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.08. The company had revenue of $383.60 million during the quarter, compared to analyst estimates of $373.29 million. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 earnings per share. On average, research analysts expect that Integra Lifesciences Holdings Corp will post 2.73 EPS for the current year.

In other Integra Lifesciences news, COO Glenn Coleman sold 3,650 shares of the company’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $55.00, for a total transaction of $200,750.00. Following the transaction, the chief operating officer now directly owns 25,160 shares in the company, valued at $1,383,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Lisa Evoli sold 2,380 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $63.00, for a total value of $149,940.00. Following the transaction, the insider now owns 2,588 shares in the company, valued at $163,044. The disclosure for this sale can be found here. Insiders sold 21,186 shares of company stock valued at $1,277,791 over the last quarter. 4.50% of the stock is currently owned by company insiders.

A number of equities research analysts have recently issued reports on IART shares. JMP Securities upped their price target on Integra Lifesciences to $75.00 in a research report on Thursday, July 25th. BTIG Research set a $70.00 price target on Integra Lifesciences and gave the company a “buy” rating in a research report on Wednesday, July 24th. Royal Bank of Canada set a $66.00 price target on Integra Lifesciences and gave the company a “hold” rating in a research report on Friday, July 26th. ValuEngine lowered Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. Finally, Wells Fargo & Co upped their price target on Integra Lifesciences from $55.00 to $68.00 and gave the company a “market perform” rating in a research report on Thursday, July 25th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $61.92.

Integra Lifesciences Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

See Also: Trading on Margin

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.